File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.18632/oncotarget.27508
- Scopus: eid_2-s2.0-85090881513
- PMID: 32256976
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Roscovitine Enhances All-trans Retinoic Acid (atra)-induced Nuclear Enrichment Of An Ensemble Of Activated Signaling Molecules And Augments Atra-induced Myeloid Cell Differentiation
Title | Roscovitine Enhances All-trans Retinoic Acid (atra)-induced Nuclear Enrichment Of An Ensemble Of Activated Signaling Molecules And Augments Atra-induced Myeloid Cell Differentiation |
---|---|
Authors | |
Keywords | ATRA roscovitine APL HL-60 Lyn |
Issue Date | 2020 |
Publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html |
Citation | Oncotarget, 2020, v. 11 n. 12, p. 1017-1036 How to Cite? |
Abstract | Although ATRA represents a successful differentiation therapy for APL, it is largely ineffective for non-APL AMLs. Hence combination therapies using an agent targeting ATRA-regulated molecules that drive cell differentiation/arrest are of interest. Using the HL-60 human non-APL AML model where ATRA causes nuclear enrichment of c-Raf that drives differentiation/G0-arrest, we now observe that roscovitine enhanced nuclear enrichment of certain traditionally cytoplasmic signaling molecules and enhanced differentiation and cell cycle arrest. Roscovitine upregulated ATRA-induced nuclear c-Raf phosphorylation at S259 and S289/296/301. Nuclear c-Raf interacted with RB protein and specifically with pS608RB, the hinge region phosphorylation controlling E2F binding and cell cycle progression. ATRA-induced loss of pS608RB with cell cycle arrest was associated with loss of RB-sequestered c-Raf, thereby coupling cell cycle arrest and increased availability of c-Raf to promote differentiation. Part of this mechanism reflects promoting cell cycle arrest via ATRA-induced upregulation of the p27 Kip1 CDKI. Roscovitine also enhanced the ATRA-induced nuclear enrichment of other signaling molecules traditionally perceived as cytoplasmic promoters of proliferation, but now known to promote differentiation; in particular: SFKs, Lyn, Fgr; adaptor proteins, c-Cbl, SLP-76; a guanine exchange factor, Vav1; and a transcription factor, IRF-1. Akin to c-Raf, Lyn bound to RB, specifically to pS608RB. Lyn-pS608RB association was greatly diminished by ATRA and essentially lost in ATRA plus roscovitine treated cells. Interestingly Lyn-KD enhanced such ATRA-induced nuclear signaling and differentiation and made roscovitine more effective. ATRA thus mobilized traditionally cytoplasmic signaling molecules to the nucleus where they drove differentiation which were further enhanced by roscovitine. |
Persistent Identifier | http://hdl.handle.net/10722/283756 |
ISSN | 2016 Impact Factor: 5.168 2023 SCImago Journal Rankings: 0.789 |
PubMed Central ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rashid, A | - |
dc.contributor.author | Duan, X | - |
dc.contributor.author | Gao, F | - |
dc.contributor.author | Yang, M | - |
dc.contributor.author | Yen, A | - |
dc.date.accessioned | 2020-07-03T08:23:37Z | - |
dc.date.available | 2020-07-03T08:23:37Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Oncotarget, 2020, v. 11 n. 12, p. 1017-1036 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/10722/283756 | - |
dc.description.abstract | Although ATRA represents a successful differentiation therapy for APL, it is largely ineffective for non-APL AMLs. Hence combination therapies using an agent targeting ATRA-regulated molecules that drive cell differentiation/arrest are of interest. Using the HL-60 human non-APL AML model where ATRA causes nuclear enrichment of c-Raf that drives differentiation/G0-arrest, we now observe that roscovitine enhanced nuclear enrichment of certain traditionally cytoplasmic signaling molecules and enhanced differentiation and cell cycle arrest. Roscovitine upregulated ATRA-induced nuclear c-Raf phosphorylation at S259 and S289/296/301. Nuclear c-Raf interacted with RB protein and specifically with pS608RB, the hinge region phosphorylation controlling E2F binding and cell cycle progression. ATRA-induced loss of pS608RB with cell cycle arrest was associated with loss of RB-sequestered c-Raf, thereby coupling cell cycle arrest and increased availability of c-Raf to promote differentiation. Part of this mechanism reflects promoting cell cycle arrest via ATRA-induced upregulation of the p27 Kip1 CDKI. Roscovitine also enhanced the ATRA-induced nuclear enrichment of other signaling molecules traditionally perceived as cytoplasmic promoters of proliferation, but now known to promote differentiation; in particular: SFKs, Lyn, Fgr; adaptor proteins, c-Cbl, SLP-76; a guanine exchange factor, Vav1; and a transcription factor, IRF-1. Akin to c-Raf, Lyn bound to RB, specifically to pS608RB. Lyn-pS608RB association was greatly diminished by ATRA and essentially lost in ATRA plus roscovitine treated cells. Interestingly Lyn-KD enhanced such ATRA-induced nuclear signaling and differentiation and made roscovitine more effective. ATRA thus mobilized traditionally cytoplasmic signaling molecules to the nucleus where they drove differentiation which were further enhanced by roscovitine. | - |
dc.language | eng | - |
dc.publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html | - |
dc.relation.ispartof | Oncotarget | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | ATRA | - |
dc.subject | roscovitine | - |
dc.subject | APL | - |
dc.subject | HL-60 | - |
dc.subject | Lyn | - |
dc.title | Roscovitine Enhances All-trans Retinoic Acid (atra)-induced Nuclear Enrichment Of An Ensemble Of Activated Signaling Molecules And Augments Atra-induced Myeloid Cell Differentiation | - |
dc.type | Article | - |
dc.identifier.email | Rashid, A: arashid2@hku.hk | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.18632/oncotarget.27508 | - |
dc.identifier.pmid | 32256976 | - |
dc.identifier.pmcid | PMC7105165 | - |
dc.identifier.scopus | eid_2-s2.0-85090881513 | - |
dc.identifier.hkuros | 310705 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1017 | - |
dc.identifier.epage | 1036 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1949-2553 | - |